BioXcel Therapeutics Inc
BTAI
NASDAQ
Biotechnology
$1.19
USD
+0.06 (+5.31%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $35.05M
Volume 2.0M
Revenue
$680,000
TTM
-63.3%
YoY
Gross Margin
36%
TTM
+397.7%
YoY
Net Income
$-75.33M
TTM
-88.0%
YoY
Operating Cash Flow
$-57.38M
TTM
+13.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 0.1 | 0.1 | 0.3 | 0.2 |
YoY Growth | -71.1% | -89.1% | -54.2% | -30.1% | +22.6% |
Cost of Revenue | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 |
Gross Profit | 0.2 | 0.0 | 0.1 | 0.2 | -0.1 |
Selling, General & Administrative | 5.7 | 5.6 | 5.4 | 3.8 | 7.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
Total Operating Expenses | 10.3 | 15.9 | 14.3 | 10.5 | 10.1 |
Operating Income | -10.1 | -15.9 | -14.2 | -10.3 | -10.2 |
EBITDA | -10.0 | -15.8 | -14.0 | -10.2 | -10.2 |
Other Income / Expense | 6.6 | 0.7 | -12.5 | 1.8 | 1.5 |
Total Other Income / Expense | 2.8 | -3.3 | -16.7 | -2.3 | -2.5 |
Income Before Income Taxes | -7.3 | -19.2 | -30.9 | -12.5 | -12.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -7.3 | -19.2 | -30.9 | -12.5 | -12.7 |
Consolidated Net Income / Loss | -7.3 | -19.2 | -30.9 | -12.5 | -12.7 |
Net Income Attributable to Common Shareholders | -7.3 | -19.2 | -30.9 | -12.5 | -12.7 |
Basic EPS | -$1.50 | -$2.45 | -$2.18 | -$0.57 | -$0.54 |
Diluted EPS | -$1.50 | -$2.45 | -$2.18 | -$0.57 | -$0.54 |
Basic Shares Outstanding | 4.8M | 7.8M | 14.2M | 22.0M | 23.6M |
Diluted Shares Outstanding | 4.8M | 7.8M | 14.2M | 22.0M | 23.6M |